A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis
CompletedCTIS2024-512891-37-00
Antwerp University HospitalMultiple Sclerosis
End: 2025-11-06Target: 48Updated: 2024-11-25